




**Supplemental Figure 1: Anti-IRF-5 antibody specificity and gating strategy.** a) WT and *IRF5*<sup>-/-</sup> THP-1 cells were restimulated with either IMQ or PMA+IMQ and IRF-5 expression was assessed by flow cytometry. Graphs show a) representative FACS plots and the percentage of IRF-5 positive cells, and b) the frequency of IRF-5 nuclear localization. c) Representative FACS plots showing the gating strategy used to determine the frequency of cells positive for Annexin V, IRF-5<sup>+</sup>, IFN $\gamma$ <sup>+</sup>, and DR5<sup>+</sup> in total CD4<sup>+</sup> T cells or CD45RA<sup>+</sup> and CD45RA<sup>-</sup> CD4<sup>+</sup> T cells in PBMCs isolated from PHI and HIV<sup>free</sup> individuals.




**Supplemental Figure 2: DR5 expression in IRF-5<sup>+</sup> cells.** Graphs show a) the percentage of CD45RA<sup>+</sup> and CD45RA<sup>-</sup> CD4<sup>+</sup> T cells expressing IRF-5 and b) the percentage of DR5<sup>+</sup> CD4<sup>+</sup> T cells in PHI and HIV<sup>free</sup> individuals; c) the percentage of IRF5 expressing DR5<sup>+</sup> CD4<sup>+</sup> T cells, and d) the percentage of IRF5<sup>+</sup> DR5<sup>+</sup> CD4<sup>+</sup> T cells expressing CD45RA<sup>+</sup>/IFN $\gamma$ <sup>+</sup>/CD4<sup>+</sup> T cells in PHI patients. Data are presented as the mean  $\pm$  SD. The Mann-Whitney *U*-test and the Kruskal-Wallis test followed by the Dunn's multiple comparison test were used to determine statistical significance, \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ ,  $n=10$ . e) Graph represents correlation between Annexin V and DR5 expressions in memory CD4<sup>+</sup> T cells from PHI patients. The Spearman *r* test was used to determine statistical significance, \*  $p < 0.05$ ,  $n=10$ .




**Supplemental Figure 3: Representative FACS plots showing the gating strategy** used to determine the frequency of apoptotic, dead, IRF-5<sup>+</sup>, and Fas<sup>+</sup> CD4<sup>+</sup> T cells or to gate naïve, effector and memory CD4<sup>+</sup> T cells from ART HIV-1<sup>+</sup>, EC, and HIV<sup>free</sup> donors.



**Supplemental Figure 4: IRF-5 expression does not correlate with Annexin V expression in EC but correlates with REG3a concentration in the serum of ART HIV-1<sup>+</sup> donors.** a) Graph represents correlation between Annexin V and IRF5 expressions in memory CD4<sup>+</sup> T cells from EC. The Spearman r test was used to determine statistical significance, \*  $p < 0.05$ ,  $n=10$ . b-c) The concentration of REG3a in the donors' serum was assessed by ELISA. Graphs show b) REG3a concentrations in the serum of male and female ART HIV-1<sup>+</sup> participants, and c) the correlation between IRF-5 expression and REG3a serum concentrations. Data are presented as the mean  $\pm$  SD. The Friedman's test and the Dunn's multiple comparison test were used to determine statistical significance, \*  $p < 0.05$ ,  $n=6$ . For c), the Spearman r test was used to determine statistical significance, \*  $p < 0.05$ ,  $n=12$  (6 female and 6 male donors).




**Supplemental Figure 5:** Graphs represent correlations between a) *TLR7* and IRF-5 expressions and b) *TLR7* and Annexin V expressions in memory CD4<sup>+</sup> T cells from EC. Spearman  $r$  test was used to determine statistical differences \*  $p < 0.05$ ,  $n=9$ . c-f) Purified CD4<sup>+</sup> T cells from HIV-1<sup>+</sup> and HIV<sup>free</sup> donors were stimulated for 24h with  $\alpha$ CD3/ $\alpha$ CD28. Graphs show c) the percentage of IRF-5<sup>+</sup> total CD4<sup>+</sup> T cells and the percentage of d) IRF-5<sup>+</sup>, e) apoptotic cells, and f) dead cells in memory CD4<sup>+</sup> T cells. Data are presented as the mean  $\pm$  SD. The Friedman's test and the Dunn's multiple comparison test were used to determine statistical significance, \*  $p < 0.05$ ,  $n=6$ .




**Supplemental Figure 6: IRF-5 inhibitory peptides limit Fas-mediated apoptosis in memory CD4<sup>+</sup> T cells.** Four different IRF-5 blocking peptides and the control peptide were tested for their cytotoxicity and their capacity to block IRF-5 in CD4<sup>+</sup> T cells. Graphs show a) the percentage of live PBMCs from HIV<sup>free</sup> donors upon incubation with IRF-5 inhibitory peptides at various concentrations, and b) IRF-5 nuclear localization in unstimulated and c,d) IRF-5 nuclear localization in IMQ-stimulated CD4<sup>+</sup> T cells from ART HIV-1<sup>+</sup> and HIV<sup>free</sup> donors in the presence or absence of 10μM of the indicated peptides or peptide mix. Data are presented as the mean ± SD, n=3.


A




**B**




**C**




**D**



**E**



**Supplemental Figure 7: CD4<sup>+</sup> T cells from male and female participants display similar responses.** a) Purified CD4<sup>+</sup> T cells from female and male ART HIV-1<sup>+</sup> and HIV<sup>free</sup> donors were treated with IMQ or medium alone; 12h later rFasL or medium were added to the culture and the cells were incubated for further 18h for a total of 30h incubation at 37°C. Graphs show the percentage of apoptotic memory CD4<sup>+</sup> T cells from a) female and c) male donors, the percentage of dead memory CD4<sup>+</sup> T cells from b) female and d) male participants, and e) CASP8 mRNA levels in memory CD4<sup>+</sup> T cells from male (left graph) and female (right graph) donors after 30h stimulation. Data are presented as the mean  $\pm$  SD. The Friedman's test and the Dunn's multiple comparison test were used to determine statistical significance, \* p < 0.05, n=6.



**Supplemental Figure 8: Stimulation of memory CD4<sup>+</sup> T cells in the presence of DAMPs and IFN $\beta$  promotes the upregulation of TLR7 and predisposes cells to Fas-mediated apoptosis.** Purified CD4<sup>+</sup> T cells from HIV<sup>free</sup> individuals were treated *in vitro* for 24 h with 10 ng/ml IFN $\beta$  in the presence or absence of 10% v/v supernatant containing apoptotic material (AM, supernatant of staurosporine-treated cells), before stimulation with  $\alpha$ CD3/ $\alpha$ CD28 for 24h. Graphs show a) the percentage of IRF-5<sup>+</sup>, b) the percentage of apoptotic and c) the percentage of death memory CD4<sup>+</sup> T cells. CD4<sup>+</sup> T cells from HIV<sup>free</sup> individuals were treated as described above and additionally incubated with rFasL for further 18h after  $\alpha$ CD3/ $\alpha$ CD28 stimulation. Graphs show d) the percentage of IRF-5<sup>+</sup>, e) the percentage of apoptotic and f) the percentage of death memory CD4<sup>+</sup> T cells. Data are presented as the mean  $\pm$  SD. The Friedman's test and the Dunn's multiple comparison test were used to determine statistical significance, \*  $p < 0.05$ ,  $n=6$ .